GlobeNewsWire
13 Nov 2025, 13:36 UTC · 45w ago
Verdict
Headline takes no side. We score MBRX +0.60 across four claims — strongly bullish.
+0.60strongly bullish
More positive than 78% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Moleculin expects to complete treatment for the first 45 subjects in the MIRACLE trial by Q1 2026, with initial unblinded data to follow.
More positive than 87% of claims this week
Blinded response activity for the Annamycin trial is currently tracking within the company's expected range.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 67% of claims this week
60% of the target subjects for the first planned interim unblinding have already consented to the study.
More positive than 54% of claims this week
Some European trial sites have experienced enrollment impacts due to hospital bed shortages.
More negative than 62% of claims this week
Which stocks this story touches
More positive than 78% of ticker scores this week
The company reported positive momentum in recruitment and blinded response activity tracking within the expected range for its pivotal MIRACLE study.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Invezz
3h ago
−95.4%
Price is moving against the score
$0.5626 vs $12.19 close before publication (Nov 12) · not market-adjusted
MBRX chart →
